EUCTR2021-000148-23-DE进行中（未招募）1 期
68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial
niversity Hospital Essen0 个研究点目标入组 155 人开始时间: 2021年3月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Proven or suspected tumor type:
- •Colorectal
- •Endometrial
- •Esophageal
- •Glioma/GBM
- •Head and neck
- •Hepatocellular carcinoma
- •Multiple Myeloma
- •Neuroendocrine
- •Pancreatic
- •Renal cell carcinoma
- •Unknown primary
- •2. At initial staging or re-staging of disease
- •3. At least one detectable tumor lesion with any diameter >1 cm
- •4. Intended or performed surgery or biopsy of tumor within 8 weeks before or after enrollment
- •5. Age =18 years
- •6. Patient Eastern Cooperative Oncology Group (ECOG) performance status =2.
- •7. Women of child bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, can only be included after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test within 24 h before radiopharmaceutical application.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •1. Patient cannot give consent for the study
- •2. Patient can not lie flat or tolerate 68Ga-FAPI-46 PET imaging
- •3. Prior external beam radiation therapy (EBRT) within 1 month of enrollment to tumor lesions intended for surgery or biopsy
- •4. Prior chemotherapy, immunotherapy, biologic or targeted oncologic therapy within 1 month of enrollment
- •5. Unwillingness or inability to comply with study and follow-up procedures
- •6. History of disease or condition that may critically interfere with participation in this study at the discretion of the investigators
- •7. Pregnant, lactating, or breast-feeding women
- •8. Women of child bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study, unless they are using highly effective methods of contraception during the interventional period. Highly effective contraception methods include:
- •True sexual abstinence: defined as refraining from heterosexual intercourse, when this is in line with the
- •preferred and usual lifestyle of the patient. Periodic
- •abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception.
- •Vasectomised partner is a highly effective birth control method if the partner is the sole sexual partner of the study participant and the vasectomised partner has received medical assessment of the surgical success.
- •Bilateral tubal occlusion.
- •Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:
- •- intravaginal
- •- transdermal
- •Progestogen-only hormonal contraception associated with inhibition of ovulation:
- •- injectable
- •- implantable
- •Placement of an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
- •9. Post-menopausal women are allowed to participate in this study. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms), or six months of spontaneous amenorrhea with serum folliclestimulating hormone (FSH) levels > 40mIU/mL or have had surgical bilateral ophorectomy or bilateral salpingectomy or hysterectomy or tubal ligation at least six weeks prior to screening. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
- •10. Sexually active males must use a condom during intercourse during the interventional period. A condom is required to be used also by vasectomized men in order to prevent delivery of the study compound via seminal fluid
- •11. QTcF >470 msec for females and QTcF >450 msec for males on screening electrocardiogram (ECG) or history of congenital long QT syndrome
- •12. Known or expected hypersensitivity to 68Ga-68-FAPI-46 or any
- •of the relevant excipients.
研究者
相似试验
已完成
2 期
68Ga-FAPI-46 PET for Imaging of FAP Expressing CancerTumor, SolidNCT05160051University Hospital, Essen158
进行中（未招募）
1 期
FARE TrialRectal cancerCTIS2023-506594-35-00Amsterdam UMC45
招募中
1 期
Diagnostic PET/CT (Positron Emission Tomography/Computed Tomography) examination with the radiotracer 68Ga-FAPI-46 to assess fibroblast activation and risk in solid tumorsEUCTR2022-003786-38-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS50
招募中
1 期
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)CTIS2024-511659-17-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.100
进行中（未招募）
1 期
68Ga-FAPI-46 PET/CT for predicting histological response in triple-negative breast cancerBreast cancerCTIS2023-507860-37-00Institut Curie300